Special Authority data for pembrolizumab and nivolumab for June 2020
Request for Special Authority data on pembrolizumab and nivolumab.
13 August 2020
Dear [name and contact details redacted]
REQUEST FOR INFORMATION
Thank you for your request dated 20 July 2020 under the Official Information Act 1982 (OIA) in response to the information provided by PHARMAC on 19 June 2020 for OIA 2019-20-187.
You have asked for Special Authority data on pembrolizumab and nivolumab for June 2020. The information you have requested is tabulated below.
|
Pembrolizumab - SA1615, SA1657 |
||||||
|
Month submitted |
Initial Applications |
Approvals - initial |
Renewal Applications |
Approval - Renewal |
Total applications |
Total approvals |
|
2020-06-01 |
24 |
23 |
46 |
43 |
70 |
66 |
|
Nivolumab - SA1656, SA1602, SA1617 |
||||||
|
Month submitted |
Initial Applications |
Approvals - initial |
Renewal Applications |
Approval - Renewal |
Total applications |
Total approvals |
|
2020-06-01 |
<10 |
<10 |
0 |
0 |
<10 |
<10 |
Note that PHARMAC has changed information in the tables to protect the privacy of natural persons (section 9(2)(a) of the OIA). This is when the data refers to numbers of less than 10 individuals. In these instances, the value has been changed to <10.
As required under the OIA, we also considered whether, in the circumstances, the withholding of this information was outweighed by other considerations which render it desirable, in the public interest, to make this information available. In this case we did not consider that the public interest outweighed the reasons for withholding the information.
Please note you have the right, by way of complaint under section 28(3) of the OIA to an Ombudsman, to seek an investigation and review of our decision.
We trust that this information answers your queries. We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.
Yours sincerely
Rachel Read
Manager, Policy and Government Services